On this page you will find information for pharmacists involved in the RECOVERY Trial, including FAQs and HRA Pharmacy Assurance.
December 2022: RECOVERY trial sotrovimab has received a further expiry date extension, to 30 months. This will require relabelling existing stock and any new stock received. Please see sotrovimab 30 month expiry documents below.
December 2022: We are aware that some packs of molnupiravir and Paxlovid used in RECOVERY currently have a short shelf life. RECOVERY uses NHS stocks of these antivirals, and the DHSC is currently arranging batch specific variations to extend shelf life for both.
RECOVERY Trial pharmacy briefing document and FAQs (This version was updated on 20 January 2023)
Sotrovimab expiry date extension